Baxter International (BAX) Projected to Post Quarterly Earnings on Thursday

Baxter International (NYSE:BAX) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $0.48 per share and revenue of $2.59 billion for the quarter. Baxter International has set its FY 2025 guidance at 2.450-2.550 EPS and its Q1 2025 guidance at 0.470-0.500 EPS.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%. The business had revenue of $2.75 billion for the quarter, compared to analyst estimates of $2.67 billion. On average, analysts expect Baxter International to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Baxter International Trading Up 3.6 %

NYSE:BAX opened at $29.64 on Thursday. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. Baxter International has a twelve month low of $26.25 and a twelve month high of $41.06. The company has a market cap of $15.20 billion, a P/E ratio of -23.16, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64. The business has a 50 day moving average price of $32.39 and a two-hundred day moving average price of $32.51.

Baxter International Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Friday, February 28th were given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 2.29%. The ex-dividend date of this dividend was Friday, February 28th. Baxter International’s dividend payout ratio (DPR) is currently -53.13%.

Analyst Upgrades and Downgrades

BAX has been the topic of a number of recent research reports. Barclays upped their target price on Baxter International from $39.00 to $41.00 and gave the stock an “overweight” rating in a report on Monday, March 10th. JPMorgan Chase & Co. dropped their price objective on Baxter International from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Friday, February 21st. The Goldman Sachs Group initiated coverage on shares of Baxter International in a research note on Wednesday, February 26th. They issued a “buy” rating and a $42.00 target price for the company. Finally, Argus raised shares of Baxter International from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $38.56.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.